• 1-800-880-6491

BioPharma

Partner with MCI to Successfully Translate Your BioPharma Story for Investors and Stakeholders to Achieve Your Capital Markets Objectives.

Contact UsSubscribe
Investor Sentiment Snapshot

BioPharma

Investor Sentiment Analysis

BioPharma

Investor sentiment toward biopharma in 2025 remains cautiously optimistic. Investors are seeking a balance between innovation and commercial execution, showing preference for companies with diversified portfolios, proven revenue streams, and late-stage pipeline assets. Capital is flowing toward firms advancing oncology, immunology, and rare disease therapeutics, especially those demonstrating pricing power and market access. Investors are closely monitoring macroeconomic pressures, political rhetoric around drug pricing, and leadership changes at U.S. health agencies. For Canadian and U.S. biopharma issuers, sustained communication on pricing strategy, reimbursement, and regulatory progress is critical to investor confidence.

The BioPharma Sector's

Challenges

Biopharma companies are navigating several headwinds in 2025:

  • Political and regulatory pressure on drug pricing and rebate reform
  • Slower-than-expected recovery in vaccine and COVID-related product demand
  • Investor concerns around capital efficiency and M&A overreach
  • Increasing public skepticism and political polarization on vaccine policy
  • Rising costs of R&D, particularly for AI-integrated and data-heavy development models
The BioPharma Sector's

Opportunities

Despite volatility, the biopharma industry is primed for long-term value creation:

  • Significant unmet needs in oncology, rare diseases, and neurodegenerative conditions
  • Breakthroughs in platform technologies (e.g., mRNA, cell therapy, bispecifics)
  • Resurgence in cross-border dealmaking and licensing activity
  • Adoption of AI and data science to streamline clinical development
  • Strategic reallocation toward prioritized late-stage assets to drive near-term value
Implications for your

Investor Relations & Capital Markets Strategy

In the current environment, biopharma investor relations must evolve to meet heightened expectations around transparency, access, and strategic clarity. Investors expect issuers to demonstrate disciplined capital deployment, especially following recent criticisms of bloated pipelines and misaligned acquisitions. With U.S. drug pricing under political scrutiny and Canadian firms operating within publicly funded healthcare systems, IR teams must clearly articulate pricing strategies, access pathways, and reimbursement assumptions.

From a capital markets strategy perspective, companies must tailor their investor engagement to align with shifting preferences—emphasizing risk-adjusted returns, milestone visibility, and differentiated pipelines. North American investors are scrutinizing regulatory pathways, particularly in light of recent shakeups in U.S. public health leadership. Clear communication around regulatory submissions, advisory committee outcomes, and health economics data will enhance investor confidence.

Given continued interest in partnerships, strategic licensing deals, and bolt-on acquisitions, IR must ensure management communicates how such transactions enhance long-term value. Canadian-listed biopharma companies should also consider dual-listing strategies and cross-border roadshows to attract U.S. institutional capital. Consistent messaging across investor materials, press releases, and corporate presentations is essential to building trust in this complex and dynamic sector.

Our Capabilities
MCI Capabilities

Activist Resolution

MCI Capabilities

Corporate Communications

MCI Capabilities

Capital Markets
Strategy

MCI Capabilities

Crisis
Communications

MCI Capabilities

Debt and Equity
Offerings

MCI Capabilities

Financial
Reporting

MCI Capabilities

Design &
Branding

MCI Capabilities

Digital
Technologies

MCI Capabilities

ESG &
Sustainability

MCI Capabilities

Investor Perception
Studies

MCI Capabilities

Initial Public
Offerings

MCI Capabilities

Ongoing Investor
Relations

MCI Capabilities

Investment
Grade Events

MCI Capabilities

Market
Coaching

MCI Capabilities

Market
Connect

MCI Capabilities

Market
Turnaround

MCI Capabilities

Transaction
Communications

Learn more about the capital markets

Access Our Insights

Stock Splits and Consolidations (Reverse stock splits)

Stock Splits and Consolidations – The Risks and Benefits to Capital Market Performance

 Stock Splits and Consolidations – The Risks and Benefits to Capital Market Performance 1024 576 Tom McMillan

Stock splits and reverse stock splits do not create value on their own. However, they play an important role in how public companies manage liquidity, accessibility, and investor perception. This article explains when stock splits and share consolidation make sense, the risks involved, and how boards and management teams should frame these decisions within a broader capital markets strategy.

Returning Capital to Shareholders

Returning Capital to Shareholders: Dividends, Special Payouts, and Share Buybacks

 Returning Capital to Shareholders: Dividends, Special Payouts, and Share Buybacks 1024 576 Todd Coakwell

Returning capital to shareholders is a key part of a public company’s capital markets strategy. After funding growth and operations, management must decide how to give excess cash back to shareholders as part of their value creation plan. In this post, we explain the main ways of returning capital to shareholders – regular dividends, special…

Implementing AI in your capital markets function

Implementing Artificial Intelligence in Your Capital Markets Program

 Implementing Artificial Intelligence in Your Capital Markets Program 1024 576 Tom McMillan

Artificial intelligence has already become table stakes for corporate capital market functions. Laggards in adopting AI are already watching their valuation lag behind companies that are taking advantage of the efficiency, scale, and enhanced engagement made possible by AI.

Preparing for Your Initial Public Offering

Preparing for Your Initial Public Offering & Getting it Right

 Preparing for Your Initial Public Offering & Getting it Right 1024 576 Tom McMillan

Your company’s initial public offering (“IPO”) will set the tone for how the capital markets perceive your company for years. When companies get it right, the IPO becomes a foundation for durable access to capital and long-term success. However, when companies fall short in their IPO preparation process, the damage can linger and hold down the company’s valuation over the long-term.

Building an Investment-Grade Investor Presentation

Building an Investment-Grade Investor Presentation

 Building an Investment-Grade Investor Presentation 1024 576 Todd Coakwell

Investors judge the quality of your company through the quality of its investor presentation and other materials. The look, feel, brand, and clarity of the investor presentation will determine how the company, its prospects, and management credibility is perceived.

It is management's responsibility to enhance the trading liquidity of their company's stock

Enhance Your Company’s Trading Liquidity

 Enhance Your Company’s Trading Liquidity 1024 576 Tom McMillan

Management teams that shrug their shoulders when confronted with poor trading liquidity are failing their shareholders. By ignoring strategies to improve their trading liquidity, and turning stock holders into stuck-holders, management teams doom their companies to a discount. Companies can enhance their trading liquidity and valuation by maximizing market access and awareness while activating demand through a robust conversion funnel.

Broker-Dealer Relationships – Building a Marriage of Equals

 Broker-Dealer Relationships – Building a Marriage of Equals 1024 576 Tom McMillan

Choosing the right broker-dealers to work with is nearly as important as choosing who to marry. The right partner will support you – the wrong partner will leave you on the sidelines. Companies must partner with firms whose capabilities, sector focus, and size align with the company’s own. In short, companies should seek a marriage of equals when it comes to the sell-side.

Share buybacks, NCIBs, and repurchases can hurt your company's share performance

The Hidden Dangers of Share Buybacks and NCIBs

 The Hidden Dangers of Share Buybacks and NCIBs 1024 576 Tom McMillan

Share buybacks often look like a winning strategy. They boost EPS, return cash, and signal confidence. But for companies with small floats or weak liquidity, buybacks can seriously undermine value. This post explains why, and offers a checklist for boards to consider before repurchasing shares.

Artificial Intelligence Can Hurt IR

Artificial Intelligence: How It Can Help and Hurt Investor Engagement

 Artificial Intelligence: How It Can Help and Hurt Investor Engagement 1024 576 Tom McMillan

AI tools like chatbots and outreach agents promise efficiency for IR teams. But if they reduce human contact, they can hurt your investor conversion funnel. This post shows when AI helps — and when it harms investor engagement — and offers practical guardrails for IR professionals.

Contact Us

The capital markets can be bewildering, even to the most experienced management teams. We believe that most executives are committed to maximizing shareholder value, but poorly executed investor relations can lead to valuation loss, reputational damage, employee attrition, deal failure, and even shareholder revolt.

MCI has helped its clients unlock billions of dollars in market value through a proven system that delivers sound messaging, branding, and engagement strategies. Over the past two decades our team has been involved in $5.7 billion in corporate actions that include $3.1 billion in acquisitions and $2.6 billion in financings-all successful.

MCI can help you resolve unfair valuation discounts and get the most out of your company’s public listing. Contact us today to engage our data driven, results focused process to unleash real progress.